Consolidated Statement of Stockholders' Equity - USD ($)	Total	Common stock issued for cash at $5.90 per share	Novartis	Amgen	Preferred Stock	Common Stock	Common Stock Common stock issued for cash at $5.90 per share	Common Stock Novartis	Common Stock Amgen	Additional Paid-In Capital	Additional Paid-In Capital Common stock issued for cash at $5.90 per share	Additional Paid-In Capital Novartis	Additional Paid-In Capital Amgen	Accumulated Other Comprehensive Income (loss)	Accumulated Deficit	Non-controlling Interest
Beginning Balance, Amount at Sep. 30, 2014	$ 165,985,255				$ 18	$ 147,026				$ 391,164,558					$ (224,771,159)	$ (555,188)
Beginning Balance, Shares at Sep. 30, 2014					18,300	54,656,936
Exercise of warrants, Amount	401,876					$ 81				401,795
Exercise of warrants, Shares						79,828
Exercise of stock options, Amount	101,870					$ 29				101,841
Exercise of stock options, Shares						28,758
Stock-based compensation	10,232,897									10,232,897
Exercise of exchange rights, Amount	3,072					$ 5				3,067
Exercise of exchange rights, Shares						5,250
Preferred stock converted to common stock, Amount					$ (2)	$ 1,316				(1,314)
Preferred stock converted to common stock, Shares					(2,648)	1,316,215
Common stock- Restricted Stock Units vesting, Amount	(26,029)					$ 136				(26,165)
Common stock- Restricted Stock Units vesting, Shares						136,307
Stock issuances			$ 25,000,000					$ 3,321				$ 24,996,679
Stock issuances, Shares								3,321,383
Foreign currency translation adjustments	(136,425)													$ (136,425)
Net loss	(91,940,882)														(91,940,882)
Ending Balance, Amount at Sep. 30, 2015	109,621,634				$ 16	$ 151,914				426,873,358				(136,425)	(316,712,041)	(555,188)
Ending Balance, Shares at Sep. 30, 2015					15,652	59,544,677
Exercise of warrants, Amount	3,691,398					$ 853				3,690,545
Exercise of warrants, Shares						852,532
Exercise of stock options, Amount	133,869					$ 37				133,832
Exercise of stock options, Shares						37,187
Stock-based compensation	11,595,816									11,595,816
Common stock- Restricted Stock Units vesting, Amount	(670,765)					$ 428				(671,193)
Common stock- Restricted Stock Units vesting, Shares						428,187
Stock issuances		$ 43,231,435		$ 9,000,000			$ 7,627		$ 1,257		$ 43,223,808		$ 8,998,743
Stock issuances, Shares							7,627,119		1,256,983
Foreign currency translation adjustments	143,874													143,874
Net loss	(81,723,002)														(81,723,002)
Ending Balance, Amount at Sep. 30, 2016	95,024,259				$ 16	$ 162,116				493,844,909				7,449	(398,435,043)	(555,188)
Ending Balance, Shares at Sep. 30, 2016					15,652	69,746,685
Exercise of stock options, Amount	$ 271,931					$ 136				271,795
Exercise of stock options, Shares	135,730					135,730
Stock-based compensation	$ 7,891,595									7,891,595
Exercise of exchange rights, Amount	17,150					$ 5				17,145
Exercise of exchange rights, Shares						5,000
Preferred stock converted to common stock, Amount					$ (16)	$ 2,671				(2,655)
Preferred stock converted to common stock, Shares					(15,652)	2,670,989
Common stock- Restricted Stock Units vesting, Amount	(403,261)					$ 481				(403,742)
Common stock- Restricted Stock Units vesting, Shares						481,212
Stock issuances				$ 12,420,000					$ 1,746				$ 12,418,254
Stock issuances, Shares									1,745,810
Foreign currency translation adjustments	25,783													25,783
Net loss	(34,380,295)														(34,380,295)
Ending Balance, Amount at Sep. 30, 2017	$ 80,867,162					$ 167,155				$ 514,037,301				$ 33,232	$ (432,815,338)	$ (555,188)
Ending Balance, Shares at Sep. 30, 2017						74,785,426